The Rise Of Domestic Veress Needles And Market Restructuring Under China’s Volume-Based Procurement (VBP)

https://en.wikipedia.org/wiki/Veress_needle

Historically, China's Veress needle market was dominated by multinationals (e.g., Johnson & Johnson, Medtronic, Karl Storz), commanding premium prices. Recently, propelled by advancements in domestic medical device manufacturing and supportive government policies, Chinese-made Veress needles have made significant strides in technology, quality, and market share. Particularly under the impetus of Volume-Based Procurement (VBP), the market landscape is undergoing profound restructuring. This article analyzes these trends and implications.

Technological Progress of Domestic Brands:

• Closing the Gap:​ Leading domestic firms have invested in advanced CNC grinders and laser welders, optimizing processes to approach/exceed import standards in material usage (316L SS), tip grinding precision, and obturator assembly.
• Strengthened QC:​ Increasing numbers hold ISO 13485 certification and NMPA Class III registration, implementing robust quality systems ensuring product consistency and reliability.
• Emerging Innovation:​ Differentiation efforts include developing extended-length needles (150mm) for obese patients, refining tip geometry to reduce insertion force, and enhancing obturator spring sensitivity.

Profound Impact of VBP:

• Drastic Price Reduction:​ VBP's volume-for-price mechanism has slashed procurement costs. While multinationals lowered prices to retain share, domestic brands gained a steeper competitive edge.
• Market Share Shift:​ Domestics achieved higher bid win rates due to cost-effectiveness, rapidly expanding market presence. In several regions, domestic brands now dominate public hospital formularies.
• Industry Consolidation:​ VBP favors firms with scale, cost control, and proven quality consistency. Smaller, inefficient players are exiting, concentrating resources among top-tier domestic manufacturers.
• Innovation Imperative:​ Margin compression on standard products forces reinvestment into R&D for higher-value innovations (e.g., smart/visualized needles).

Challenges & Opportunities for Domestic Substitution:

Challenges:

Brand Perception:Lingering clinician skepticism regarding quality requires time and clinical outcome data to overcome.

High-End Penetration:Multinationals retain advantages in premium hospitals and complex procedures.

Global Compliance:Exporting demands navigating diverse regulatory landscapes (FDA, CE MDR), posing higher barriers.

Opportunities:

Policy Support:Government initiatives (priority procurement, innovation green channels) bolster domestic adoption.

Cost Advantage:Natural efficiencies in sourcing, manufacturing, and labor enhance competitiveness in VBP.

Diverse Clinical Needs:Expanding minimally invasive indications create niches for tailored domestic solutions.

Maturing Supply Chains:Improved domestic ecosystem stability supports cost control and scalability.

Future Outlook:

Domestic Veress needle market share will likely continue growing, transitioning from "catching up" to "running parallel" and eventually "leading" in specific segments. Success requires sustained R&D, unwavering quality focus, brand building, and clinical education. For healthcare providers, VBP necessitates objective evaluation of domestic product performance-balancing fiscal responsibility with uncompromised patient safety. Ultimately, the ascent of domestic Veress needles promises reduced healthcare costs and advanced accessibility for minimally invasive surgery patients nationwide.